AxoGen (NASDAQ:AXGN – Get Free Report) had its price target lifted by investment analysts at Canaccord Genuity Group from $50.00 to $55.00 in a report released on Thursday,Benzinga reports. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. According to MarketBeat, AxoGen presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.00. Get AxoGen alerts:Check Out Our Latest Stock Report on AxoGenAxoGen Stock PerformanceNASDAQ:AXGN traded up $0.83 during trading hours on Thursday, reaching $42.20. Insiders Place Their BetsIn related news, Director Amy Mcbride Wendell sold 1,647 shares of AxoGen stock in a transaction dated Friday, May 8th.